3 progressive phases: (1) a left-right limb discrimination task (recognition), (2) imagined movements of the affected limb, and (3) mirror therapy. 14, 15 The most recent practice guidelines for the treatment of CRPS state that GMI should be used as a first-line treatment, 3 as evidence shows that a 6-week GMI program offers better reduction in pain and improvements in functional gains when compared with conventional rehabilitation program. 14, 16, 17 However, despite these positive results, the treatment effect size remains modest and for up to a third of the patients, the symptoms of CRPS often persist for years. 13, 14, [16] [17] [18] Moreover, considering that a recent Cochrane review rated the quality of evidence for GMI as low, 19 it appears appropriate to investigate new therapeutic approaches that could enhance current nonpharmacological treatments for CRPS. As suggested by the most recent practice guidelines, motor cortex stimulation, through Transcranial Direct Current Stimulation (tDCS), is as an experimental therapy that could be instated in parallel to GMI. 3 Other studies have shown that the combination of tDCS with a nonpharmacological treatment (eg, visual illusion of walking) in the treatment of neuropathic pain related to spinal cord injury resulted in a mean reduction of 29.7% in pain intensity compared with 11.0% to visual illusion combined with placebo tDCS. 20 Similar results were also observed in a case study involving a patient with CRPS type I, which found beneficial effects of tDCS on chronic pain and quality of life after the addition of tDCS to sensorimotor rehabilitation. 21 To our knowledge, outside these discussed there are no other studies that have explored tDCS effects' in CRPS patients.
Given that a recent Cochrane review 10 concluded that tDCS may not deliver important benefits in chronic pain, a combined approached is justified. Thus, the main goal of this study was to explore the effectiveness of anodal tDCS in the treatment of CRPS in addition to GMI on the severity of pain in patients with CRPS type I. We hypothesized that the combination of tDCS with GMI would lead to better outcomes than GMI alone.
MATERIALS AND METHODS

Participants
In accordance with the Declaration of Helsinki, the study was approved by the Ethics Review Boards of the Centre Hospitalier Universitaire de Sherbrooke and the Hoˆpital Charles-Le Moyne (Que´bec, Canada). This trial was also registered at ClinicalTrials.gov (NCT01960400). All participants (22 selected of the 62 potential candidates) were patients recruited from the pain clinics of these 2 hospitals and all provided their written informed consent before the start of the study. Participants received no financial compensation for their participation. Eligible patients were (1) aged 18 years and older; (2) had a medical diagnostic of CRPS type 1 confirmed by an anesthesiologist or a neurosurgeon based on Budapest Research Criteria for research 3 ; (3) did not have other chronic pain conditions, dyslexia, visual impairment, neurological, psychological or motor disorder; (4) did not have any history of brain implants, severe head trauma or headaches; and finally (5) if the patient was taking pain medication, their pharmacological intervention had to be stable (unchanged dose) over the last 4 weeks before the beginning of the study. Furthermore, participants were required not to modify their pharmacological and/or nonpharmacological treatments throughout the 10 weeks of the trial (see Table 1 for overview of patient characteristics).
Experimental Design
A randomized, parallel, single-blind design including 2 treatment options was used (GMI + active tDCS; GMI + sham tDCS). This design was selected to provide initial evidence regarding the effectiveness of the combined treatment for further large-scale studies. 22 As the prevalence of CRPS is low, sampling was nonprobabilistic and patients consisted of a consecutive sample of all eligible patients. After the verification of the admissibility criteria, patients were randomly assigned to the experimental group (GMI + active tDCS) or the placebo group (GMI + sham tDCS) using a randomized block design, to balance groups in regards to the duration of symptoms. Hence, a list was made for randomization into blocks (2Â 2), one block for treatment group and one block for duration of symptoms ( r6 mo and >6 mo since diagnosis of CRPS type 1). To avoid a potential concealment bias, the randomization sequence was concealed from the investigators, where only an independent research agent held the allocation list. The research team did not know the exact size of the blocks until the study was completed.
GMI Intervention
Home Exercise
The GMI intervention was performed at home using the Recognise Flash Cards set, consisting of 25 left and 25 right matching images (upper limb or lower limb) and a mirror box (NOIgroup, Adelaide City West, South Australia). The participants performed the GMI therapy at home, 10 minutes per session, 3 times per day, 6 times a week, for 6 weeks. 23 The description and settings of the GMI process are detailed in appendix (Appendix A, Supplemental Digital Content 1, http://links.lww.com/CJP/ A446). Before the beginning of each phase, the clinician carefully explained the GMI program to the participant. To further enhance standardization, a guide explaining the treatment parameters was given to all participants. Furthermore, at each visit, the GMI program was reviewed with the participant and, if needed, the clinician provided the necessary adjustments to follow the standardized application of the program.
tDCS Intervention
Interventions in the experimental (clinical) settings: tDCS was delivered according to the method described by Fregni et al 24 and in accordance with the safety guidelines related to tDCS application. 25 Direct current was delivered using a battery-driven constant current stimulator (DCStimulator NeuroConn, Germany) coupled to salinesoaked (0.9% NaCl) sponge electrodes (5Â 7 cm). Anodal stimulation was delivered over M1; the anode was placed over C3 or C4 position in the 10/20 system) for the EEG electrode position, contralateral to the affected limb, and the cathode over the opposite supraorbital area (ie, ipsilateral to the affected limb). 25 The choice of stimulation sites and stimulation parameters was based on previous studies showing improvement of neuropathic pain conditions. 20, 26 A constant current of an intensity of 2 mA was applied for 20 minutes (30 s ramp up, 30 s ramp down), each day, for 5 consecutive days (Monday to Friday) during the first and the second weeks of GMI (Fig. 1A) . To help retain the potential effects of the neurostimulation, the tDCS was also applied simultaneously with GMI once a week (Mondays) during the 2 other phases until the end of the 6 weeks GMI program, for a total of 14 treatment sessions. For the group receiving the sham tDCS, the electrodes were placed in the same position as for the active stimulation using the same tDCS stimulator at same stimulation intensity (2 mA), but the device automatically turned off after 30 seconds of stimulation (placebo mode). This type of sham stimulation has been shown to reliably blind participants. 27 
Timing of GMI and tDCS Interventions
All combined GMI and tDCS intervention occurred in the experimental (clinical) setting. During weeks 1 and 2 (Monday to Friday), the first GMI treatment of the day was combined with tDCS; the other 2 prescribed GMI treatments for that day were performed at home. In addition, on Saturday or Sunday, participants realized the GMI program 3 times per day (a total of 10 treatments combined in laboratory and 26 treatments GMI at home). For weeks 3 to 6, GMI + tDCS treatments were done on Monday mornings, and all other daily GMI sessions were undertaken by the patient at home, for a total of 4 treatments combined in laboratory and 68 GMI sessions at home (Fig. 1A) .
Accordingly, when patients were present in the research setting, the tDCS was installed and started. After 8 minutes of stimulation (of the 20), they were asked to start performing the GMI exercises (Fig. 1B) . This was based on the observations of Nitsche and Paulus, 28 who found that anodal stimulation of about 9 to 13 minutes leads to a more robust and long-lasting increase in cortical excitability. 
Fidelity of the Intervention
To ensure the fidelity of the application of the combined treatment within the 3 clinicians, and to ensure that the results obtained were dependent on the intervention and not on the clinician, specific strategies were put in place: (1) the production of an application guide-as recommended by Sidani and Braden 29 -containing a detailed description of the combined interventions, the materials needed and the procedure to be followed by the research team members; (2) a priori standardization of clinicians; and (3) individual follow-up of the intervention for each participant by the lead investigator (E.L.).
Outcome Measures (Dependent Variables)
The choice of the outcome measures was made in accordance with the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT) guidelines 30 and included measures of pain severity and interference with function. All patients completed a selfadministered questionnaire to assess the clinical characteristics of pain. Measurements took place before (T0), after 6 weeks of treatment (T1), and 1 month after the end of the treatment (T2). The primary outcome measure was pain severity and measured by the Brief Pain Inventory ShortForm (BPI-SF). 31 The BPI-SF includes 4 questions on pain levels, where subjects were asked to rate intensity on a scale of 0 (no pain) to 10 (worst possible pain) in regards to: (1) pain at its worst in the last 24 hours, (2) pain at its least in the last 24 hours, (3) average pain over the last 24 hours, and (4) pain right now (present pain). The score of each subscale ranges from 0 to 10 for a total score of 40. The minimum clinically important difference (MCID) is an average score of >2/10 for each of the 4 subscales). 32 The following secondary outcome measures were also assessed.
Impact of Pain on Daily Function
The BPI-SF also had 7 questions measuring the impact of pain on daily function, including the impact on general activity, sleep, mood, enjoyment of life, walking ability, ability to work and perform daily tasks and relationships with other people. 33 Subjects were asked to rate how their pain interfered with these items over the previous 24 hours using a numerical rating scale ranging from 0 (does not interfere) to 10 (completely interferes). The total score of this section of the BPI-SF ranges from 0 to 70.
Quality of Life
The SF-12 short form (SF12v2) 34 is a general healthrelated quality of life questionnaire that consists of 12 Likert scale questions derived from the original SF-36 questionnaire. 35 It covers 8 domains (ie, physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health). The scores on each of these domains are summarized into 2 scales: the SF-12 Physical Component Summary (SF-12 physical component summary) and the SF-12 Mental Component Summary. Scores for each summary scale, ranging from 0 to 100, were calculated with standard scoring algorithms and normalized using the US general population values (mean 50 [SD 10]), with lower scores indicating worse health-related quality of life. 35 The MCID for the SF-12 PhCS is Z8.8/100 and Z9.3/100 for the SF-12 MCS. 36 
Kinesiophobia
The Tampa Scale of Kinesiophobia, 37 a 17-item selfreport measure, was used to assess fear of movement and injury/(re)injury. The total score ranges from 17 to 68, with higher scores representing stronger fear-avoidance beliefs. 38 The minimal detectable change (MDC) for the Tampa Scale of Kinesiophobia is >4.8. 39 
Pain Catastrophizing
The Pain Catrastrophizing Scale (PCS) 40 was used to evaluate the feelings, thoughts, and emotions related to pain catastrophizing. It is a self-administered questionnaire consisting of 13 items included in 3 subscales. The total score ranges from 0 to 52 points, with higher scores representing stronger pain catastrophizing. 40 The MDC for the PCS is >9.1. 39 
State Anxiety
The State-Trait Anxiety Inventory 41 is used to assess the state of anxiety at the moment. 42 The total score ranges from 20 to 80, where higher total score is, higher is the anxiety about an event. 
Symptoms of Depression
The Beck Depression Inventory (BDI-II), 43 which includes 21 statements, was used to measure symptoms and attitudes specific to depression. 44 Each statement is graded from 0 to 3, and higher total score indicates more severe depressive symptoms. The MCID is a Z17.5% reduction from baseline (Z11/63). 45 
Measures of Compliance, Adverse Effects, and Blinding
The completion of a daily diary at home by all the patients throughout the study enabled us to monitor the implementation of the GMI program as well as compliance. Patient blinding was assessed at the end of the trial by asking each patient to guess which treatment they believed to have received. Throughout and after all the GMI or tDCS treatments, patients were also asked to note and report any side effects they experienced.
Statistical Analysis
Sample size estimates were based on the results of the study of Soler et al, 20 which aimed to evaluate the efficacy of tDCS combined with another treatment modality, the visual illusion of walking. In their study, the severity of pain, assessed using a numerical scale from 0 to 10, had an average reduction of 29.7% ± 5.0% for the tDCS + visual illusion of walking group, compared with an average reduction of 11.0% ± 14.0% for the sham tDCS + visual illusion of walking after treatment. To consider that there is a significant difference between both groups, pondering that the average percentage of pain relief would be 29.7% for the experimental group and 11.0% for the placebo group, we estimated a mean difference of B20% between groups, with a SD of 14.0% (a = 0.05 and b = 1 to 0.80). Hence, the sample size of each group was estimated at 10 participants. Considering a dropout rate of 10%, a total of 11 participants per group were recruited. At T0, the normality of the data (sociodemographic characteristics and dependent variables) was first tested using the Kolmogorov-Smirnov test. According to the results, either parametric tests (Student T tests; normal distribution) or nonparametric tests (Wilcoxon signed-rank tests; asymmetric distribution) were performed. For categorical data, the w 2 tests or Fisher exact tests (if frequency of a cell of the crosstab was 5 or less) were used to compare outcomes between the 2 groups.
To compare the effectiveness of interventions (between-group differences), a mixed-model ANOVA (time Âgroup interaction) was used. Because of a difference in total duration of each measurement time (T0-T1 = 6 wk; T1-T2 = 4 wk), a simple contrast (vs. T0) and nonpolynomial analysis was selected from the IBM SPSS software. Age, as a covariate was included in the model, as it was found to be significantly different between both groups to obtain an adjusted P-value. However, for all the continuous dependent variables, age did not significantly impact the results and therefore were not retained. To compare the percent of change of each individual against the recognized MCID, defined as the statistically determined smallest change in a treatment outcome to be identified as important for the patients, 46 we used the Fisher exact test for between groups comparison at T1 and T2. All statistical analyzes were performed using IBM SPSS Statistics 22.0 version of Mac OS and Graph Pad Software (2015) (www.graphpad.com/quickcalcs/).
RESULTS
Descriptive Data
All subjects were enrolled between May 2012 and June 2014. Figure 2 shows the CONSORT flowchart for our study. Twenty-two patients, all meeting the admissibility criteria, were included.
At baseline (T0), sociodemographic and clinical characteristics of both groups did not differ significantly ( 
Primary Outcome Measure: Pain Severity (BPI-SF)
Overall, change in pain severity (BPI-SF) did not significantly differ between groups, where only a tendency was observed (P = 0.065) ( Table 2 ). The only group Âtime interaction was found in the subscale measuring pain severity (present pain P = 0.046), which was not maintained at the 1-month postintervention (T2) (Fig. 3) . Also, no difference in the proportion of patients who reached the MCID threshold was found between both groups at T1 and at T2, even for the present pain subscale, where a 42% reduction in present pain intensity was observed at T1 for the experimental group.
Secondary Outcome Measures
Complete results for the secondary variables are also presented in Table 2 . We found no significant between group differences (time Âgroup interaction) at T1 and T2 regarding the impact of pain on global physical functioning, on the physical and mental health quality of life and on depressive symptoms. No difference in the proportion of patients who reached the MCID threshold was found between both groups for either variable, at T1 and at T2. For the fear of movement, pain catastrophizing and state anxiety, the analysis revealed a statistically significant time Âgroup interaction at T1 only, which showed lower scores for the experimental group. However, these were not maintained at T2. Yet, considering that the group differences for the first 2 variables are less than the known MDC, it certainly did not reach a clinically significant level and has to be interpreted with caution.
Assessment of Compliance and Blinding
In regards to compliance, we noted from the daily diary that all participants reported completing their GMI At the end of the treatments (T1), participants were asked in which treatment group they believed they were allocated (experimental or placebo). Thirteen participants (59.1%) responded correctly. Nine participants (81.8%) from the experimental group compared with 7 participants (63.6%) from the placebo group responded that they had received the active tDCS treatment regimen. No statistically significant difference was found between groups in the assessment of blinding (P = 0.635).
Adverse Effects of Treatment
Regarding the undesirable effects of the GMI treatment, 3 participants reported that specific images had generated a temporary increase in pain (B30 min), mainly during the phase 2 of the protocol. Two strategies were proposed to these participants: to remove the images that provoked pain and to reduce the time of subsequent sessions (before the onset of pain). Only one participant from the experimental group reported minor fasciculation during the exercises in phase 3. As a strategy to avoid this discomfort, the participant was invited to perform his exercises more slowly, by granting short breaks of a few seconds. Regarding the undesirable effects of the tDCS, 3 participants from the experimental group and 2 participants from the placebo group complained of minor headaches after tDCS, especially during the second week of phase 1. In all cases, the headaches disappeared within 2 or 3 hours following the tDCS session. These participants reported taking acetaminophen after their tDCS session, which had a beneficial effect on their headaches. Only 1 participant from the experimental group reported a slight reddening and itching on his head (around the location of the anode) during the second week of treatment. Two participants from the experimental group and one participant of the placebo group reported feeling more tired than usual on a number of occasions after their tDCS treatment. Finally, 4 participants (18.2%) declared having been indisposed by a sting/burning sensation under the electrodes during the first minute of active tDCS. Adding saline water (B5 mL per electrode) and applying a slight pressure on the electrodes immediately reduced this discomfort. No tDCS sessions were interrupted due to undesirable or adverse effects.
DISCUSSION
The main objective of this study was to produce preliminary evidence regarding the therapeutic effectiveness of the combination of GMI and tDCS for the management of CRPS. In regards to our main outcome measure (pain severity), we found no statistically significant group differences immediately and 1 month after the 6 weeks of treatment. Yet, considering that a tendency was observed (P = 0.06) and that for one subscale of our main dependent variable a positive outcome was found, our results may suggest that this treatment regimen could induce positive outcomes on a very short-term perspective. Considering this tendency, a larger sample-size, thus greater power, could have lead to a true and significant effect. However, although stronger than GMI alone, these observations lead us to believe that, in our sample, the analgesic effects of GMI + tDCS are modest at the very and also very shortlived. As for group differences in regards to kinesiophobia, pain catastrophizing, and state anxiety following 6 weeks of GMI + active tDCS, they need to be interpreted with caution as none reached a clinically significant difference.
Short-term Benefits of GMI + Active tDCS
The combination GMI + active tDCS (experimental group) resulted in a 42% reduction of present pain intensity scores at T1; considering this change is greater than B30%, it represents a clinically important difference. 47 In comparison, this positive short-term effect is somewhat comparable with the 29.7% pain reduction obtained by Soler et al 20 with a comparable treatment approach (tDCS + visual illusion of walking), but in a different neuropathic pain population. However, this pain reduction should be interpreted with caution, as the effect is dependent on a subscale of only one of our main variable. In fact, the lack of significant effect in our main variable (pain severity) appears to be more similar to reports of a recent Cochrane systematic review, which concludes that tDCS may not deliver statistically significant effects in individuals with chronic pain. 10 However, as we observed no changes in the placebo group (sham tDCS)-pain reduction was only observed in the experimental group (active tDCS)-the specific effects of the tDCS could explain the greater analgesia in present pain observed at T1. Given our results, a third group, which would have only received the active tDCS without GMI, could have helped us to determine the indebted effect specific to the tDCS. However, this was not performed due to: (1) the explorative nature of the study (proof of concept), (2) the feasibility issues in terms of recruiting participants, and (3) ethical reasons given that GMI is recommended in current CRPS practice guidelines, 3 it would have been arguable to provide only a treatment which is supposed to be an add-on to our patients. The effect of tDCS on present pain management could be an avenue to explore further, as the effect of tDCS was only sustained in the short term.
Lack of Pain Reduction 1 Month After Treatment (T2)
For the management of pain, the most commonly used protocol consisted of 20-minute anodal stimulation of M1 for 5 consecutive days, which may lead to significant analgesic after-effects lasting for 2 to 6 weeks. 48 According to the same parameters, the application of 10 sessions of anodal tDCS should generate long-lasting analgesic effects, up to 60 days after the end of treatments. 26 However, although this dosage was observed in addition to a weekly session until the end of GMI treatment, the results we obtained (GMI + tDCS) did not demonstrate a significant analgesic after-effect lasting 1 month postintervention.
An element that could explain the overall lack of effect might be related to anticonvulsants that might have decreased the effects of anodal stimulation after a single session of tDCS. 49 This lack of pain reduction observed might suggest that patients with anticonvulsants may respond less to this treatment. In fact, 73% and 64% of the patients took anticonvulsants in the experimental and placebo groups, respectively, which could potentially have lessened the tDCS effect. 49, 50 To increase the effect and the chances of longer-lasting pain relief, perhaps a more adequate and/or personalized pharmacological approach could help modulate treatment effects, 51 a factor that was not manipulated in our study, but only partially controlled.
Lack of Treatment Effect in the Placebo Group
Although not the main focus of our study, the absence of a "no-treatment" group also forbids us to draw any clear conclusion to answer questions regarding if GMI alone (placebo group) was helpful, harmful or of no value. However, participants in the placebo group (GMI + sham tDCS) showed no positive treatment effect, which again is in discordance to the results of some previously published studies, who found a reduction in pain intensity after GMI alone. 14, 16, 17 This lack of effect of the GMI observed in our study could partly be explained by 2 factors: (1) duration of CRPS symptoms: although the distribution of participants in the 2 groups (experimental and placebo) during randomization was successful, our "chronic" CRPS patients all had a much longer duration of symptoms (B36 mo) compared with the participants in Moseley's 14, 16, 17 previous publications (B14 mo). Studies from other groups also reported poor results with the use of GMI for chronic CRPS patients. For instance, McCabe et al 52 found an immediate analgesic effect using mirror therapy on acute-subacute CRPS patients, but reported no positive effect for chronic CRPS patients (> 14 mo). The same observations were reported by Johnson et al, 53 who even reported an increase in pain of + 37.5% during GMI for their chronic CRPS patients (B23 mo). Hence, it appears that GMI has equivocal results for patients with a longer duration of CRPS and clearly needs further investigation. (2) Minor discrepancies between treatment regimen: the other factor that could explain the absence of treatment effect for the placebo group may be related to our GMI intervention protocol, which somewhat varied from the one used in Moseley's 17 published clinical trial (see Appendix A, Supplemental Digital Content 1, http://links.lww.com/CJP/ A446, for comparisons); our recommended frequency for GMI exercises was lower (3 exercise sessions per day) than Moseley's 14, 16, 17 hourly recommendation. But many audited patients in these previous studies reported that complying with exercises every waking hour was not feasible for them (75% compliance rate was reported). Our methodological choice regarding the frequency of the exercises was based on previous positive findings 23 and the fact that this exercise regimen was more respectful of their daily routine and quality of life during the intervention. 29, 54 This methodological choice also probably contributed to the perfect compliance we observed for our 2 groups. Nevertheless, the lower frequency of the exercises remains a possible explanation of the lack of result of the GMI.
Finally, another possible explanation for the lack of effect in our placebo group is related to the absence of progression of the training load. The use of software proposed by Moseley, 17 instead of Recognise Flash Cards, would have made it possible to graduate the requirements of the exercises. However, the parameters of use of the GMI are not entirely known and are difficult to reproduce. In short, further investigations are required to determine if the NOI group's Recognise Flash Cards provide equivalent results to the use of the adaptive software.
Knowing that (1) the effectiveness of GMI has been demonstrated by three separate trials of GMI, all conducted by the same research team and (2) all were relatively small trials (13 to 37 participants), a high risk of bias may be present. 19 In fact, another independent research team could not, as in our study, confirm the effectiveness of the GMI. 53 Failure of the real-world implementation of GMI suggests that better understanding of both GMI methodology and its interaction with other treatment modality is required to ensure that GMI research results can be translated into clinical practice. Further studies would be necessary to determine the optimal frequency of exercises, while considering its pragmatic application in real-life.
Potential Bias Related to the Blinding Procedures
When we initially developed this protocol, we relied on the most robust available evidence to develop the tDCS protocol. It was then accepted that the use of a 2 mA stimulation presumed an effective blinding. 20, 21, 26 But recently, O'Connell et al 55 demonstrated that a 2 mA tDCS might not be associated with effective blinding when compared with the sham commonly using this procedure. Since our study had reported superior efficacy of active stimulation over sham and adequate participant blinding, assessor blinding was not possible. While we cannot predict the degree of influence that inadequate blinding may have had in our study, nonspecific effects of interventions are known to be important in such clinical conditions. 56, 57 Further, there is evidence that incomplete blinding leads to exaggerated effects in clinical studies with subjective outcomes, 58 and that placebo effects are larger with physical placebo interventions. 57 Thus, the O'Connell et al 55 study contends that clinical studies that have used 2 mA tDCS should be interpreted with renewed caution. Using intensities of 1 mA in future research may represent a more methodologically sound option, although it is plausible that reducing the intensity may reduce potential efficacy. Future studies of tDCS may benefit from other methods to optimize blinding, for example, de facto masking in which the treatment is not blinded but both treatments are presented as the active one. 59 
Future Considerations
Maybe better outcomes could be obtained if the treatment was individually adjusted according to the main neurophysiological process that explains the development and/or maintenance of CRPS symptoms, that is peripheral versus spinal versus central hypersensitivity or sympathetic neural system. 1 On the nasis of the principle that management of painful pathologies should be incorporated within a biopsychosocial framework, patients could be offered treatments grounded on the multiple different mechanisms driving pain and disability. Maybe, in our protocol, too much emphasis was directed toward nervous system hypersensitivity (GMI and tDCS mostly target supraspinal hypersensitivity) and less on cognitive-emotional factors (ie, psychogenic drivers of pain or pain avoidance-behaviors) or environmental factors, such as attitudes of others or beliefs regarding work. It is possible that a patient-centered approach, based on how the person responds to treatment with the addition of other targeted therapeutic modalities, could induce a more efficient management of CRPS. 60 Also, further investigations are required to elucidate the elements of GMI intervention that determine success and to identify the characteristics of responders. A better understanding of the relative weight of this each factor could allow to better personalizing the treatment protocol.
CONCLUSIONS
The current report was the first to investigate the added-value of tDCS to GMI in the treatment of CRPS type I. Our results show no significant added value of adding a series of tDCS in addition GMI treatments for reducing pain severity in patients with chronic CRPS type I.
